Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 49.35B P/E 33.77 EPS this Y 4.40% Ern Qtrly Grth 19.30%
Income 1.54B Forward P/E 27.91 EPS next Y 2.70% 50D Avg Chg -9.00%
Sales 6.2B PEG 3.15 EPS past 5Y 9.17% 200D Avg Chg -2.00%
Dividend N/A Price/Book 7.66 EPS next 5Y 7.89% 52W High Chg -25.00%
Recommedations 2.50 Quick Ratio 2.32 Shares Outstanding 602.40M 52W Low Chg 20.00%
Insider Own 0.90% ROA 12.28% Shares Float 596.36M Beta 1.13
Inst Own 85.53% ROE 22.02% Shares Shorted/Prior 11.38M/6.34M Price 80.38
Gross Margin 76.38% Profit Margin 23.74% Avg. Volume 2,811,916 Target Price 76.58
Oper. Margin 27.22% Earnings Date Oct 23 Volume 3,495,317 Change -2.04%
About Edwards Lifesciences Corporatio

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Corporatio News
11/19/24 November 2024's Top Undervalued Small Caps With Insider Activity
11/13/24 US transcatheter tricuspid valve repair market grows by over 50% since launch in Q2 2024
11/13/24 We Like The Quality Of Edwards Lifesciences' (NYSE:EW) Earnings
11/09/24 Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insight
11/01/24 Edwards Lifesciences Corporation (EW) Fell Due to Missed Earnings Expectations and Weak Guidance
10/31/24 Edwards, Medtronic and Inari share trial data at TCT conference
10/30/24 Data Presented at TCT Reinforce Edwards Lifesciences’ Commitment to Structural Heart Innovation
10/30/24 TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation
10/29/24 JPMorgan views Edwards Lifesciences TAVR data positively
10/28/24 Bernstein Lifts Edwards Lifesciences Rating, Sees Balanced Risk-Reward in Tavr Market
10/28/24 Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients
10/28/24 International Markets and Edwards Lifesciences (EW): A Deep Dive for Investors
10/27/24 Edwards Lifesciences price target raised to $85 from $80 at Barclays
10/26/24 Earnings Beat: Edwards Lifesciences Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
10/25/24 Edwards Skids On Weak Expectations For Its Bread-And-Butter Moneymaker
10/25/24 EW Q3 Earnings Match Estimates, Revenues Miss, Stock Falls
10/25/24 Edwards Lifesciences Corp (EW) Q3 2024 Earnings Call Highlights: Strong Growth in TMTT Sales ...
10/24/24 Compared to Estimates, Edwards Lifesciences (EW) Q3 Earnings: A Look at Key Metrics
10/24/24 Edwards Lifesciences: Q3 Earnings Snapshot
10/24/24 Edwards Lifesciences Reports Third Quarter Results
EW Chatroom

User Image 11thestate Posted - 1 day ago

$EW stockholders filed a claim against Edwards Lifesciences for misleading them about the growth prospects of its TAVR platform. You can check if you are eligible and file for the payment here: https://11thestate.com/cases/edwards-lifesciences-investor-suit

User Image Estimize Posted - 3 days ago

Wall St is expecting 0.55 EPS for $EW Q4 [Reporting 01/30 AMC] http://www.estimize.com/intro/ew?chart=historical&metric_name=eps&utm_conten

User Image wolf12631 Posted - 6 days ago

$EW securities fraud lawsuits

User Image 11thestate Posted - 1 week ago

$EW stockholders filed a claim against Edwards Lifesciences for misleading them about the growth prospects of its TAVR platform. You can check if you are eligible and file for the payment here: https://11thestate.com/cases/edwards-lifesciences-investor-suit

User Image jewell69 Posted - 1 week ago

$EW b now 3:52 pm est 66.2525 11/8 and 40 more 1 minute later 66.23 took profits in oct at 70.11 on 10/17 and so forth it worked well, did same w/ $DXCM but now 2 scary w/ $AAPL COMINg OUT (FAR IN FUTURE) W/ A DIABETES MONITOR TOOL ON i-FONES. BOTh WERE CLOBBERED AROUND 7/21 (-21% OR SO NOT SURE) . TOP hOLDINgS OF $IHI

User Image mamunmoral66 Posted - 1 week ago

$UPST had an excellent earnings report, even beating the whisper $EPS. It's difficult looking 1–2 months into the future based on how Q4 is doing, but based on $EW and the daily chart, a potential of $75 is a possibility by year-end. Especially considering how it jumped after hours on Thursday.

User Image 11thestate Posted - 2 weeks ago

$EW stockholders filed a claim against Edwards Lifesciences for misleading them about the growth prospects of its TAVR platform. You can check if you are eligible and file for the payment here: https://11thestate.com/cases/edwards-lifesciences-investor-suit

User Image jewell69 Posted - 2 weeks ago

$EW re entry11/5/24 Type Cash Shares +125.000 Price $66.54 Amount -$8,317.50 Settlement date Nov-06-2024 10/18/2024 Sell Trade Details EW EDWARDS LIFESCIENCES COR 106 $70.11 $0.23 $7,431.43 10/15/2024 Buy Trade Details EW EDWARDS LIFESCIENCES COR 106 $69.08 -$7,322.48 stay away from $DXCM similar _ealt_ care equipment stock. t_ey fell very low same week in July 2024, but dxcm worries about $AAPL diabetes test on I-fones !! super scary.

User Image jewell69 Posted - 2 weeks ago

$EW prolly stay away; FAR away. too many recent _old reccomentations per tip ranks.

User Image jewell69 Posted - 2 weeks ago

$EW 10/28 Edwards Lifesciences (NYSE: EW) today announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating asymptomatic severe aortic stenosis (AS) and the benefits of early intervention with transcatheter aortic valve replacement (TAVR). The trial results demonstrated that asymptomatic severe AS patients randomized to Edwards TAVR experienced superior outcomes compared with guideline-recommended clinical surveillance. Trial investigators presented the data today during a late-breaking clinical trials session at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation(CRF) and published simultaneously in The New England Journal of Medicine.Click here for full release. -3.88% last 10 tradin days. looks nice

User Image geraldng01 Posted - 10/30/24

$EW looking forward to fill the gap!

User Image HammerstoneMarkets Posted - 10/30/24

$EW https://x.com/HammerstoneMar3/status/1851643068161618205

User Image G101SPM Posted - 10/29/24

#SHOWTIME ^ V.F. Corporation Investor Day (October 30) Scheduled to appear: $VFC ^ Edwards Lifesciences Corporation Analyst & Investor Meeting - TMTT Q&A Session at TCT (October 30) Scheduled to appear: $EW ^ Boston Scientific Corporation Business Update Call (October 30) Scheduled to appear: $BSX

User Image Stocksrunner Posted - 10/28/24

🚀 Monday’s hot tickers are lighting up! Today’s trending stocks: $ALAB, $ARM, $BA, $CNK, and $EW 🔥 With new analyst targets, upgrades, and fresh action, these names are set to shake things up. Are they primed for lift-off or cooling down? https://stocksrunner.com/posts/1306

User Image steven1x Posted - 10/28/24

$EW what’s the TAM for this indication? https://www.businesswire.com/news/home/20241028015602/en/Groundbreaking-Data-Demonstrate-Superiority-of-EARLY-TAVR-in-Asymptomatic-Severe-Aortic-Stenosis-Patients

User Image fjsteven Posted - 10/28/24

$EW great results https://finance.yahoo.com/news/groundbreaking-data-demonstrate-superiority-early-150000824.html

User Image Inmyzone Posted - 10/28/24

$EW why the sell off?

User Image TeresaTrades Posted - 10/28/24

Largest PUT OI decreases $DJT $CPRI $SUM $MRVL $EW

User Image KimAntony Posted - 10/28/24

$EW and also a PT raise to $85 from Barclays - https://www.streetinsider.com/dr/quote.php?q=ew

User Image KimAntony Posted - 10/28/24

$EW upgraded at Bernstein this morning - https://thefly.com/news.php?select_portfolio=0&symbol=ew&x=0&y=0&market_stories=on&hot_stocks_filter=on&rumors_filter=on&general_news_filter=on&periodicals_filter=on&earnings_filter=on&technical_analysis_filter=on&options_filter=on&syndicates_filter=on&onthefly=on&insight_filter=on&market_mover_filter=on&e_inter_filter=on&mid_wrap_filter=on&sec_wrap_filter=on&analyst_wrap_filter=on&analyst_recommendations=on&upgrade_filter=on&downgrade_filter=on&initiate_filter=on&no_change_filter=on&events=on

User Image TradingAlerts65 Posted - 10/27/24

$CSX $LUV $EW $MHK https://youtu.be/nRY5zqHOJUw

User Image LewisDaKat Posted - 10/27/24

News $EW DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Edwards Lifesciences Corporation https://marketwirenews.com/news-releases/deadline-reminder-faruqi-faruqi-llp-investigates-cla-5679156432136703.html $EW

User Image DonCorleone77 Posted - 10/27/24

$EW Edwards Lifesciences price target raised to $85 from $80 at Barclays Barclays raised the firm's price target on Edwards Lifesciences to $85 from $80 and keeps an Overweight rating on the shares. The company reported a solid beat on sales and earnings and the Q4 guidance and 2025 commentary should drive continued upward momentum for the stock, the analyst tells investors in a research note.

User Image LewisDaKat Posted - 10/26/24

$EW News Article EW FRAUD NEWS: Edwards Lifesciences Sued for Securities Fraud after Stock Plummets 31%; Investors with Losses Urged to Contact BFA Law by December 13 Court Deadline https://marketwirenews.com/news-releases/ew-fraud-news-edwards-lifesciences-sued-for-securiti-7918322423318435.html $EW

User Image EarningsCallSamurAI Posted - 10/25/24

$EW Edwards Lifesciences delivered impressive Q3 2024 results, showcasing significant growth in its core segments and strategic positioning for future expansion. The medical device leader reported a 9% increase in sales from continuing operations, reaching $1.354 billion, with particularly strong performance in its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) divisions. https://blog.earningscallsamurai.com/https-earningscallsamurai-com-edwards-lifesciences-q3-2024-results-market-leadership/

User Image EarningsCallSamurAI Posted - 10/25/24

$EW Q&A session summary from last earnings call The company expects growth from operations in 2025, with a Q4 EPS impact of $0.35 due to the elimination of Critical Care and additional acquisition-related expenses. Q4 operating margins are forecasted in the mid-20s, with targets set to reach 27%-28% by 2025. A premium pricing strategy and strong product portfolio support the company's competitive position, with growing demand across both large academic and smaller centers. Product developments, including NTAP reimbursement benefits and the 56mm EVOQUE valve approval, expand the patient base by 20%-25%, with a European launch expected mid-2025. Operationally, challenges such as a $5 million China distributor adjustment and capacity constraints are being addressed, with increased investments in heart care facilities expected to support demand growth. Check link in bio for the full report!

User Image EarningsCentral Posted - 10/25/24

$EW Earnings Call Recap for Q3 2024 https://youtu.be/yP_iEC1Q4Vk

User Image vandy84 Posted - 10/25/24

$EW despite negative results today is moving pretty decent.I feel validated

User Image wolf12631 Posted - 10/25/24

$EW sell it, Buy $BSX

User Image itsallaboutheoptions Posted - 10/24/24

$EW

Analyst Ratings
Evercore ISI Group In-Line Oct 1, 24
Citigroup Buy Oct 1, 24
Jefferies Hold Sep 18, 24
Truist Securities Hold Sep 13, 24
Oppenheimer Outperform Sep 12, 24
UBS Neutral Sep 10, 24
Barclays Overweight Sep 9, 24
Wells Fargo Overweight Sep 9, 24
Wolfe Research Peer Perform Jul 29, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
MUSSALLEM MICHAEL A Director Director Feb 05 Sell 88.06 29,350 2,584,561 4,486 02/05/24
MUSSALLEM MICHAEL A Director Director Feb 05 Option 36.75 29,350 1,078,612 33,836 02/05/24
Ullem Scott B. CVP, Chief Financial.. CVP, Chief Financial Officer Feb 01 Sell 78.29 7,255 567,994 19,248 02/01/24
Ullem Scott B. CVP, Chief Financial.. CVP, Chief Financial Officer Feb 01 Option 36.75 7,255 266,621 26,503 02/01/24
BOBO DONALD E JR CVP,Strategy/Corp De.. CVP,Strategy/Corp Development Jan 12 Sell 75.67 10,000 756,700 39,503 01/12/24
BOBO DONALD E JR CVP,Strategy/Corp De.. CVP,Strategy/Corp Development Jan 12 Option 36.75 10,000 367,500 49,503 01/12/24
MUSSALLEM MICHAEL A Director Director Jan 05 Sell 73.2 29,350 2,148,420 4,486 01/05/24
MUSSALLEM MICHAEL A Director Director Jan 05 Option 36.75 29,350 1,078,612 33,836 01/05/24
Ullem Scott B. CVP, Chief Financial.. CVP, Chief Financial Officer Dec 29 Sell 76.55 14,510 1,110,740 19,248 12/29/23
Ullem Scott B. CVP, Chief Financial.. CVP, Chief Financial Officer Dec 29 Option 36.75 14,510 533,242 33,758 12/29/23
Chopra Daveen CVP, TMTT CVP, TMTT Dec 15 Sell 78.25 7,000 547,750 23,950 12/15/23
Chopra Daveen CVP, TMTT CVP, TMTT Dec 15 Option 59.26 7,000 414,820 30,950 12/15/23
BOBO DONALD E JR CVP,Strategy/Corp De.. CVP,Strategy/Corp Development Dec 13 Sell 71.86 8,000 574,880 39,503 12/13/23
BOBO DONALD E JR CVP,Strategy/Corp De.. CVP,Strategy/Corp Development Dec 13 Option 36.75 8,000 294,000 47,503 12/13/23
Wood Larry L Global President TAV.. Global President TAVR & Surg Dec 13 Sell 71.86 8,658 622,164 213,794 12/13/23
Wood Larry L Global President TAV.. Global President TAVR & Surg Dec 13 Option 45.28 8,658 392,034 222,452 12/13/23
MUSSALLEM MICHAEL A Director Director Dec 13 Sell 74.56 29,350 2,188,336 4,486 12/13/23
MUSSALLEM MICHAEL A Director Director Dec 13 Option 36.75 29,350 1,078,612 33,836 12/13/23
Chopra Daveen CVP, TMTT CVP, TMTT Dec 06 Sell 70 3,500 245,000 23,950 12/06/23
Chopra Daveen CVP, TMTT CVP, TMTT Dec 06 Option 59.26 3,500 207,410 27,450 12/06/23
Wood Larry L Global President TAV.. Global President TAVR & Surg Nov 13 Sell 65.51 8,660 567,317 213,794 11/13/23
Wood Larry L Global President TAV.. Global President TAVR & Surg Nov 13 Option 45.28 8,660 392,125 222,454 11/13/23
BOBO DONALD E JR CVP,Strategy/Corp De.. CVP,Strategy/Corp Development Nov 13 Sell 65.19 6,000 391,140 39,503 11/13/23
BOBO DONALD E JR CVP,Strategy/Corp De.. CVP,Strategy/Corp Development Nov 13 Option 36.75 6,000 220,500 45,503 11/13/23
Ullem Scott B. CVP, Chief Financial.. CVP, Chief Financial Officer Oct 31 Option 36.75 7,255 266,621 26,503 10/31/23
Ullem Scott B. CVP, Chief Financial.. CVP, Chief Financial Officer Oct 31 Sell 62.66 7,255 454,598 19,248 10/31/23
Wood Larry L Global President TAV.. Global President TAVR & Surg Oct 13 Sell 69.94 8,660 605,680 213,794 10/13/23
Wood Larry L Global President TAV.. Global President TAVR & Surg Oct 13 Option 45.28 8,660 392,125 222,454 10/13/23
BOBO DONALD E JR CVP,Strategy/Corp De.. CVP,Strategy/Corp Development Oct 13 Sell 69.91 5,000 349,550 39,503 10/13/23
BOBO DONALD E JR CVP,Strategy/Corp De.. CVP,Strategy/Corp Development Oct 13 Option 36.75 5,000 183,750 44,503 10/13/23
Szyman Catherine M. CVP, Critical Care CVP, Critical Care Oct 10 Sell 72.68 5,000 363,400 34,814 10/10/23
Szyman Catherine M. CVP, Critical Care CVP, Critical Care Oct 10 Option 36.75 5,000 183,750 39,814 10/10/23
MUSSALLEM MICHAEL A Director Director Oct 02 Sell 68.84 29,350 2,020,454 4,486 10/02/23
MUSSALLEM MICHAEL A Director Director Oct 02 Option 36.75 29,350 1,078,612 33,836 10/02/23
Ullem Scott B. CVP, Chief Financial.. CVP, Chief Financial Officer Sep 29 Sell 69.54 7,255 504,513 19,248 09/29/23
Ullem Scott B. CVP, Chief Financial.. CVP, Chief Financial Officer Sep 29 Option 36.75 7,255 266,621 26,503 09/29/23
BOBO DONALD E JR CVP,Strategy/Corp De.. CVP,Strategy/Corp Development Sep 14 Option 36.75 4,500 165,375 44,003 09/14/23
BOBO DONALD E JR CVP,Strategy/Corp De.. CVP,Strategy/Corp Development Sep 14 Sell 73.71 4,500 331,695 39,503 09/14/23
Wood Larry L Global President TAV.. Global President TAVR & Surg Sep 14 Sell 73.63 8,660 637,636 213,794 09/14/23
Wood Larry L Global President TAV.. Global President TAVR & Surg Sep 14 Option 45.28 8,660 392,125 222,454 09/14/23
Szyman Catherine M. CVP, Critical Care CVP, Critical Care Sep 08 Sell 76 5,000 380,000 34,814 09/08/23
Szyman Catherine M. CVP, Critical Care CVP, Critical Care Sep 08 Option 36.75 5,000 183,750 39,814 09/08/23
Chopra Daveen CVP, TMTT CVP, TMTT Sep 06 Sell 76.07 8,500 646,595 23,950 09/06/23
Chopra Daveen CVP, TMTT CVP, TMTT Sep 06 Option 59.26 8,500 503,710 32,450 09/06/23
MUSSALLEM MICHAEL A Director Director Sep 05 Sell 75.86 29,350 2,226,491 4,486 09/05/23
MUSSALLEM MICHAEL A Director Director Sep 05 Option 36.75 29,350 1,078,612 33,836 09/05/23
Ullem Scott B. CVP, Chief Financial.. CVP, Chief Financial Officer Aug 31 Sell 77.79 7,255 564,366 19,248 08/31/23
Ullem Scott B. CVP, Chief Financial.. CVP, Chief Financial Officer Aug 31 Option 36.75 7,255 266,621 26,503 08/31/23
Chopra Daveen CVP, TMTT CVP, TMTT Aug 29 Sell 76.6936 1,500 115,040 23,950 08/29/23
BOBO DONALD E JR CVP,Strategy/Corp De.. CVP,Strategy/Corp Development Aug 14 Sell 79.3 4,500 356,850 39,503 08/14/23